Thomas Ciulla - Jan 4, 2023 Form 4 Insider Report for Clearside Biomedical, Inc. (CLSD)

Role: Chief Medical Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol: CLSD
Transactions as of: Jan 4, 2023
Transactions value $: $11,000
Form type: 4
Date filed: 1/6/2023, 03:27 PM
Previous filing: Jan 28, 2022
Next filing: Jan 11, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CLSD	Common Stock	Award	$6.25K	+5K	+1.68%	$1.25	303K	Jun 30, 2022	Direct	F1
transaction	CLSD	Common Stock	Award	$4.75K	+5K	+1.65%	$0.95	308K	Dec 31, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CLSD	Employee Stock Option (right to buy)	Award	$0	+188K		$0.00	188K	Jan 4, 2023	Common Stock	188K	$1.48	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2	One-fourth of the shares underlying this option vest on January 4, 2024 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date.